The Next Big Leap of VEEDA in the Arena of Clinical Research Where it has Announced the Launch of Global Oncology CRO

Ahmedabad, India (PressExposure) December 31, 2009 -- Recently VEEDA CLINICAL RESEARCH has declared that it is going to develop the oncology clinical research centre i.e. Global Oncology CRO where they will perform the oncology clinical trials and by this, they will be able to serve to a big cluster of society. Its motto is the development of oncology drug by working in pharmaceuticals and biotechnology. Here, the scientists and scholars, by utilizing all their efforts and knowledge endeavor for successful cancer clinical trials. Veeda Oncology will also provide global pharmacovigilance/surveillance to give a hand in the development of new oncology therapies. It plans to provide the support services of background research, protocol writing, study hypothesis, biostatistics, laboratory services, medical monitoring, medical writing and more. Veeda would mark its presence in the US, Europe and India to meet both the regional and global needs of its sponsors.

While denoting the structure of the new Global Oncology subsidiary CRO, Mr. Binoy Gardi, Group Managing Director, Veeda Clinical Research, said "Since July 1, 2007 we have been establishing the infrastructure for a global oncology CRO and today we are pleased to announce that both the personnel and technical infrastructure are in place, validated and tested". Whereas the president and CEO of the Oncology Division, Mr. Matt Bowman has said, "I am extremely excited to fulfill a vision of Veeda to be able to provide clients with world class oncology expertise along with rapid and cost effective access to oncology / hematology patients around the globe through our facilities in India, Europe and North America."

Mr. Bowman has over 20 years of clinical oncology experience with major pharma, biotech and oncology CRO companies. "Our headquarters are located in Columbus, Ohio and we have organized a strong leadership team with Mr. Kathy Squillace as Vice President of Clinical Operations and Mr. Dave Colborn as Vice President of Data Management and Information Technology, both of whom have over 20 years of oncology clinical development experience. In addition, we expect additional global capacity through targeted acquisitions that we anticipate completing during the next quarter".

Apurva Shah, Co- Group Managing Director, Veeda Clinical Research commented, "A key strategy that we are implementing will be our access to the oncology patient population through our unique exclusive relationships with oncology hospitals in India as well as unique relationships with oncology hospitals in Eastern Europe. In addition, our US organization has worked with virtually every major oncology investigational site. With these relationships and the rapid ability to open sites, we will be able to meet the critical accrual requirements that our sponsors are establishing to accelerate the rate of drug development".

About Veeda Oncology

Veeda Oncology is a vibrant Anglo/India CRO which brings together 20 years of clinical research expertise with the intellectual ability and tireless work ethic of the East. From First-in-Man studies to large scale Bioequivalence/Bioavailability comparator studies Veeda Clinical Research offers a fully integrated package to meet your early clinical development needs.

With state-of-the-art phase I facilities in Plymouth in the UK, Ahmadabad in India and Görlitz in Germany, fully accredited GLP laboratories, an established biometrics team in Belgium and India and a respected pre-clinical partner, Veeda CR can take your compound from pre-clinical development to proof of concept in the most timely, cost effective manner. For those clients unfamiliar with the benefits of outsourcing to India, or for those who choose to strategically spread their programs of work between two continents, Veeda CR can deliver significant cost savings combined with the complete reassurance of a UK project management service.

Press Release Source:

Press Release Submitted On: January 05, 2010 at 5:09 am
This article has been viewed 16702 time(s).